Acamprosate Decreases Alcohol Behavioral Dependence and Hypermotility After Alcohol Withdrawal But Increases Inhibitory Amino-Acids in Alcohol-Attracted Inbred Rats Using Microdialysis of the Nucleus Accumbens

Witte, Philippe De; Dahchour, Abdelkhader; Quertemont, Étienne; Durbin, Philippe; Chabac, S.

doi:10.1007/978-3-642-80193-8_5

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose and duration of exposure can be precisely controlled, and the level of intoxication can be maintained relatively stable during entire course of exposure as well as from one cycle to another [Griffin WC 3 rd et al, 2009b]. Finally, the model allows animals to be treated simultaneously with other drugs such as Acamprosate or Rimonabant dissolved in drinking water [De Witte et al, 1990; 1996]. …”

Section: Models Of Chronic Alcohol Abusementioning

confidence: 99%

Laboratory Models Available to Study Alcohol‐Induced Organ Damage and Immune Variations: Choosing the Appropriate Model

El-Guindy

Kovacs

Witte

et al. 2010

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

The morbidity and mortality resulting from alcohol-related diseases impose a substantive cost to society globally. To minimize the financial burden on society and improve the quality of life for individuals suffering from the ill effects of alcohol abuse, researchers in the alcohol field are focused on understanding the mechanisms by which alcohol-related diseases develop and progress. Since ethical concerns and inherent difficulties limit the amount of alcohol abuse research that can be performed in humans, most is performed in laboratory animals. This article summarizes the various laboratory models of alcohol abuse that are currently available and are used to study the mechanisms by which alcohol abuse induces organ damage and immune defects. The strengths and weaknesses of each of the models are discussed. Integrated into the review are the presentations that were made in the symposium “Methods of Ethanol Application in Alcohol Model – How Long is Long Enough” at the joint 2008 Research Society on Alcoholism (RSA) and International Society for Biomedical Research on Alcoholism (ISBRA) meeting, Washington, DC, emphasizing the importance not only of selecting the most appropriate laboratory alcohol model to address the specific goals of a project but also of ensuring that the findings can be extrapolated to alcohol-induced diseases in humans.

show abstract

Section: Models Of Chronic Alcohol Abusementioning

confidence: 99%

Laboratory Models Available to Study Alcohol‐Induced Organ Damage and Immune Variations: Choosing the Appropriate Model

El-Guindy

Kovacs

Witte

et al. 2010

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

show abstract

Acamprosate does not induce a conditioned place preference and reveals no state-dependent effects in this paradigm

Kratzer

Schmidt

2003

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Pharmacotherapeutic Trials in Adolescent Alcohol Use Disorders: Opportunities and Challenges

Dawes

Johnson

2004

Alcohol and Alcoholism

View full text Add to dashboard Cite

Medications as adjuncts to psychosocial treatments for adolescent alcohol use disorders hold the promise of improved efficacy over psychosocial treatments alone. Specific components should be included in the design and implementation of these medication studies. Included should be assessment of the developmental risks of the chosen medication, consideration of short-term effects on the clinical disorder, factors affecting compliance and retention, age-specific pharmacokinetics, and systematic safety monitoring. A risk-benefit analysis should be conducted on the potential benefits of the medication to decrease alcohol use versus the potential long-term effects of medication use on brain development. To select clinically meaningful subtypes of adolescents with alcohol use disorders for medication trials, classification systems should be derived from multi-factorial models of complex neurodevelopmental disorders. Multi-factorial models will be required to select samples wherein specific gene-gene and gene-environment interactions predict medication treatment response. In samples of adolescents with alcohol use disorders, clinically meaningful subtypes are likely to have differential medication treatment response as a function of age of onset, family history of disorder, and comorbid psychopathology. Findings from preclinical and treatment studies in adults, along with pilot treatment findings in adolescents, suggest that particular serotonergic agents, opioid antagonists, and agents that modulate excitatory amino acids and GABAergic transmission might be effective. Future medication trials for adolescents with alcohol use disorders should use specific combinations of medications, based on specific hypotheses involving key neurotransmitter systems that putatively modulate treatment response. Combinations of medications may have additive effects on particular neurotransmitter systems or synergistic effects across two or more neurotransmitter systems, to further decrease alcohol consumption when compared with single-agent treatment.

show abstract

Acamprosate Decreases Alcohol Behavioral Dependence and Hypermotility After Alcohol Withdrawal But Increases Inhibitory Amino-Acids in Alcohol-Attracted Inbred Rats Using Microdialysis of the Nucleus Accumbens

Cited by 3 publications

References 24 publications

Laboratory Models Available to Study Alcohol‐Induced Organ Damage and Immune Variations: Choosing the Appropriate Model

Laboratory Models Available to Study Alcohol‐Induced Organ Damage and Immune Variations: Choosing the Appropriate Model

Acamprosate does not induce a conditioned place preference and reveals no state-dependent effects in this paradigm

Pharmacotherapeutic Trials in Adolescent Alcohol Use Disorders: Opportunities and Challenges

Contact Info

Product

Resources

About